2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06F.09 Epidemiological Profile of Patients with Non-Small Cell Lung Cancer Treated at Oncologia D' or Bahia from January 2018 to December 2022.

EP.06F.09 Epidemiological Profile of Patients with Non-Small Cell Lung Cancer Treated at Oncologia D' or Bahia from January 2018 to December 2022.

Back to course

Pdf Summary

The study presents an epidemiological profile of patients with non-small cell lung cancer (NSCLC) treated at Oncologia D’Or Bahia, Brazil, between January 2018 and December 2022. Lung cancer remains the most prevalent type of cancer globally and is responsible for the highest cancer-related mortality rate. This study aims to address the limited information available on the prevalence of molecular alterations in NSCLC patients in Brazil.<br /><br />The study reviewed the medical records of 422 patients, including 173 participants. The demographics revealed a predominance of female patients (57.2%) with a median age of 67.5 years, and a high percentage were smokers (54.7%). The majority of the cases involved adenocarcinoma (82.1%), followed by squamous cell carcinoma (15.6%).<br /><br />Around 50% of the patients were diagnosed at clinical stage IV, and most did not have indications for curative thoracic surgery at the time of diagnosis. Of those who underwent surgery, lobectomy was the most common procedure performed (71%).<br /><br />Molecular testing was conducted on 62.4% of patients, revealing that 39.8% had no driver mutations. The most common mutations included EGFR (37%), ALK translocation (5.5%), KRAS G12C (4.6%), MET (4.6%), and ROS-1 (3.7%). A majority of patients with detected mutations started treatment with targeted therapy.<br /><br />The study also explored the correlation between smoking and PDL1 status, finding no significant association. The data aligns with other Brazilian studies, with smoking remaining a primary risk factor for lung cancer. However, the prevalence of smokers in this study was lower than historical national figures due to a declining trend in Brazil's overall smoking rates. The study suggests the importance of molecular testing and targeted therapy in improving NSCLC treatment, despite current logistical challenges in access and timely delivery of these tests.

Asset Subtitle

Marília Loula

Meta Tag

Speaker Marília Loula

Topic Pathology and Biomarkers

Keywords

NSCLC

Oncologia D’Or Bahia

epidemiological profile

lung cancer

molecular alterations

adenocarcinoma

smoking

molecular testing

targeted therapy

Brazil